^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan Hycela (rituximab/hyaluronidase)

    i
    Other names: SC MabThera, rHuPH20/MabThera, rHuPH20/rituximab, hyaluronidase/rituxmab
    Company:
    Biogen, Halozyme, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    1m
    Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov)
    P3, N=102, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    3ms
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Thomas Jefferson University | Trial completion date: Jun 2025 --> Apr 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase)
    3ms
    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=44 --> 5 | Trial completion date: Aug 2028 --> Nov 2026 | Trial primary completion date: Aug 2028 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    4ms
    A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Georgetown University | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan Hycela (rituximab/hyaluronidase)
    6ms
    Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, University of Washington | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Zynyz (retifanlimab-dlwr) • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    7ms
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Thomas Jefferson University | Recruiting --> Active, not recruiting | N=30 --> 4 | Trial completion date: Mar 2025 --> Jun 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase)
    7ms
    Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=13, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    cytarabine • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)
    8ms
    Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Emory University | Trial completion date: Sep 2024 --> Jun 2026
    Trial completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Rituxan Hycela (rituximab/hyaluronidase)
    9ms
    MCL R2: R-CHOP + R-HAD Vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab Vs Rituximab for Older Patients with MCL (clinicaltrials.gov)
    P3, N=623, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2025
    Trial completion • Trial completion date
    |
    lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Rituxan Hycela (rituximab/hyaluronidase)
    10ms
    A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Georgetown University | Trial completion date: Nov 2024 --> Jan 2026 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan Hycela (rituximab/hyaluronidase)
    10ms
    LOTIS-9: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=41, Terminated, ADC Therapeutics S.A. | Completed --> Terminated; The benefit-risk profile does not support continuation of the LOTIS-9 trial.
    Trial termination
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • Rituxan Hycela (rituximab/hyaluronidase)
    11ms
    Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial. (PubMed, Leuk Lymphoma)
    Subcutaneous (SC) rituximab has demonstrated advantages over intravenous (IV) administration; however, insufficient data exist on its use with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese patients with diffuse large B-cell lymphoma (DLBCL). The complete response rate was similar in both treatment arms. SC rituximab is a viable option in Chinese patients with untreated CD20-positive DLBCL, potentially reducing administration burden (ClinicalTrials.gov identifier: NCT04660799).
    P2 data • PK/PD data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Rituxan Hycela (rituximab/hyaluronidase)